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Universite´ Paris 12, 51 avenue du Mare´chal de Lattre de Tassigny, 94010 Cre´teil, FranceThe European Association for the Study of the Liver
(EASL) has established itself as the leading pan-Euro-
pean association of medical professionals dedicated to
promoting liver research and care in Europe. The grow-
ing success of EASL reﬂects the increasing medical
importance of liver diseases, as well as the quality and
vitality of European research in this ﬁeld. Leaving the
position of EASL Secretary General after four years in
the (non-oval) oﬃce gives me the opportunity to look
back at our achievements and think about the challenges
ahead.
1. EASL’s achievements
EASL was founded 45 years ago, as a small group of
investigators interested in liver research and care. Its
growth during successive years has been steady, but
slow. EASL’s metamorphosis started about 15 years
ago, thanks to the vision of Christian Bre´chot, then
EASL Scientiﬁc Secretary. The creation of the position
of Administrative Secretary, aimed at ensuring political
and administrative continuity at the highest level of the
Association, and the establishment of an embryo of a
centralized oﬃce (in fact with Isabelle Porteret, Chris-
tian’s hospital secretary, in the room beside his oﬃce)
were the ﬁrst steps towards a professional organization.
His successors (Mario Mondelli, Andrew Burroughs,
Detlef Schuppan, Jordi Bruix and Massimo Levrero)
and their Scientiﬁc Committees continued to build on
these foundations. The day of my election as EASL Sci-
entiﬁc Secretary, during the Annual Meeting in Paris in
April 2005, I found a wealthy association eﬃciently run-
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challenges of a modern scientiﬁc association in the
changing environment of the early 21st century.
The reinforcement of the political and administrative
structure of EASL appeared from the beginning as a top
priority. Switching the scientiﬁc leadership of the old
EASL ‘‘Scientiﬁc Committee” into the clear political
leadership of a reinforced, more experienced ‘‘Govern-
ing Board” was the ﬁrst step, which was achieved in
April 2006 through the approval by the EASL Business
Meeting of a new Constitution. Extending up to 48 years
the upper age limit of incoming Scientiﬁc Committee
members and increasing the total number of Governing
Board members to 10, all of diﬀerent nationalities,
including the two Educational Councillors and the Trea-
surer who have no age limit, brought invaluable experi-
ence, political skills and perspective into the EASL
Governing Board. The creation of the position of
Vice-Secretary, number 2 in the hierarchy of the Associ-
ation and future Secretary General, provided the oppor-
tunity for an eﬃcient executive pair at the highest level
of the Association, while ensuring suﬃcient training
for the incoming Secretary General. With a better form
of government, EASL was ready for further changes.
Making even more appealing an already successful
and attractive Annual Meeting was a challenge. The
growing interest of the pharmaceutical industry in liver
diseases, especially viral hepatitis, was felt to be an
opportunity to grow, but also a threat to the integrity
and diversity of our programmes. How could we surf
on the wave without being swept away? The ﬁrst deci-
sion was to create a Late-Breaker session. Since then,
these sessions have attracted cutting-edge science, a very
large audience, and exceptional media coverage, making
them one of the highlights of the EASL Annual Meet-
ing. The decision was also made to substantially increasePublished by Elsevier B.V. All rights reserved.
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sessions. The number of Early Morning Workshops
was progressively increased from 8 to 24 (12 per day)
and the number of thematic EASL Symposia from 3
to 12, while a number of educational pre-meetings, orga-
nized jointly with various sister organizations, were run
in the morning preceding the start of the EASL Post-
Graduate course. In parallel, the schedule of the Annual
Meeting sessions was deﬁnitively ﬁxed and the readabil-
ity of the scientiﬁc programme was improved. In order
to ensure that a majority of our attendees could ﬁnd
something of interest at any time during the meeting,
the sessions were organized to follow four parallel
streams, from the early morning to the end of each
day: viral hepatitis, basic science, general hepatology,
and liver transplantation/hepatocellular carcinoma (the
latter was introduced this year in Copenhagen). Room
was given to the patients’ representatives who can speak
at the Opening General Session and for the ﬁrst time this
year will organize a workshop during the Annual Meet-
ing. Through the creation of the EASL Recognition
Awards, which are presented every year during the sec-
ond General Session of the meeting, EASL has been
proud to honour the men and women who wrote the his-
tory of European and International hepatology. These
ceremonies have been deeply moving. Overall, these
changes have met with success since the attendance at
our meetings has jumped from approximately 4500 to
nearly 7500 participants at the Annual Meeting in Milan
in 2008, bringing the EASL Annual Meeting to a size
comparable to the Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD),
with a very high level of satisfaction. The EASL Annual
Meeting became ‘‘The International Liver CongressTM’
this year. This is a protected trademarked denomina-
tion, which oﬀers a number of opportunities for future
educational and scientiﬁc, as well as fundraising,
developments.
Besides its Annual Meeting, EASL runs a number of
scientiﬁc and educational activities throughout the year.
It was decided that EASL would now oﬀer full funding
and centralized practical organization of the EASL
Monothematic Conferences, allowing their scientiﬁc
organizers to concentrate on the scientiﬁc programme
only. The success of the clinical, but also the basic EASL
Monothematic Conferences is amazing. It clearly shows
the need, besides the Annual Meeting, for smaller the-
matic scientiﬁc conferences that revive the spirit of the
Association as it stood 20–30 years ago. EASL Special
Conferences were created with the intent to cover
broader topics and attract a larger number of attendees
than Monothematic Conferences. The ﬁrst EASL Spe-
cial Conference on ‘‘Hepatitis B and C Viruses Resis-
tance” convened over 800 participants in Paris,
France, in February 2008. It was jointly organized with
the AASLD, the Asian-Paciﬁc Association for the Studyof the Liver (APASL), the Latin-American Association
for the Study of the Liver (ALEH) and the International
Association for the Study of the Liver (IASL). The next
EASL Special Conference will be held in Bologna, Italy,
in autumn this year on the topics of Non-Alcoholic
Fatty Liver Disease (NAFLD)-Non-Alcoholic Steato-
hepatitis (NASH) and many other special conferences
will follow.
The past few years have seen the emergence of new
modes of communication and teaching. EASL decided
to webcast several of its educational events, including
the Annual Meeting Post-Graduate Course and EASL
Monothematic Conferences considered to be of broad
scientiﬁc interest. The lectures can be watched on the
web or podcasted for subsequent viewing. EASL web-
casts also oﬀer the unique possibility of recreating a slide
library from the full collection with a few keywords and
a simple click. More recently, the EASL e-series have
been launched as a new learning experience. E-series
are state-of-the-art presentations by world-recognized
experts providing in-depth coverage of a single topic
for on-line viewing, download or podcast. The success
of EASL’s e-learning programmes has been immediate
and early access to EASL webcasts and e-series is now
among the principal reasons for new EASL members
to apply.
The challenge of establishing a strong relationship
with other continental liver societies and building a
more global alliance has been taken very seriously. In
November 2005, a Memorandum of Understanding
was signed between EASL and AASLD, establishing a
privileged relationship between the two societies. Since
then, a number of events have been co-organized, co-
funded or endorsed by the two societies on both sides
of the Atlantic Ocean. The dialogue and cooperation
between EASL and AASLD is constant, friendly, and
constructive. Solid links have also been established with
ALEH, which materialized with the organization of an
ALEH–EASL–AASLD Post-Graduate Course during
the last ALEH Bi-Annual Meeting in Venezuela in Sep-
tember 2008. Latin-American fellows were also selected
by ALEH to attend an EASL School of Hepatology.
EASL is now present in China, where it co-organizes
every year an ‘‘EASL Annual Meeting Highlights” pro-
gramme with the Chinese Society for Liver Diseases.
International collaborations have been further expanded
by the launch, on the initiative of EASL, of an Annual
Global Liver Summit of continental liver societies’ top
executives. Better harmonization of the societies’ poli-
cies and common initiatives are expected.
As one of the two principal continental liver societies,
EASL has the crucial mission of inﬂuencing liver disease
management decisions as well as reimbursement and
management policies in Europe and abroad. The deci-
sion to launch a Clinical Practice Guidelines programme
was a major step forward for the Association. The
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and management of liver diseases on an exclusively sci-
ence-driven basis is indeed of utmost value in a medical
world too often governed by the pharmaceutical indus-
try and the regulatory agencies, with little intellectual
input from the academic world. Thanks to the involve-
ment of a number of Clinical Practice Guidelines panel-
lists and external reviewers and to the eﬀorts of the
EASL Governing Board, their success has been immedi-
ate. The outstanding impact of the EASL Clinical Prac-
tice Guidelines on Management of Chronic Hepatitis B,
in Europe and far beyond, reinforced the determination
of EASL to pursue this eﬀort and cover a large number
of clinical and therapeutic areas.
As a leading scientiﬁc association, EASL’s responsi-
bility is also to seek policy recognition for the focus of
its activity, so as to shape an environment conducive
to research and health initiatives on liver diseases. This
is why we decided to launch an ambitious Public Policy
initiative in order to address the fact that, in spite of
their high prevalence, morbidity and mortality, liver dis-
eases are all too often neglected by both national and
European Union (EU) policy-makers. EASL’s goal is
to shape the European policy environment in order to
win recognition of liver diseases as a major cause of ill-
ness and death aﬀecting too many patients in the EU.
The objectives of EASL’s European advocacy and com-
munications strategy are to make liver diseases a prior-
ity both in EU public health policy and research policy;
to raise EASL’s proﬁle as an association and to establish
its members as points of reference and key advisors to
European policy makers; and to increase awareness
amongst citizens about the causes of liver diseases, pre-
vention and screening. This is a long-term eﬀort, the
results of which will not be known for many years to
come. However, tangible results can already be
acknowledged: EASL is now recognized as the scientiﬁc
interlocutor by all major European stakeholders; the
collaboration with the patients’ associations (the Euro-
pean Liver Patient Association, ELPA, and the World
Hepatitis Alliance) has been fruitful and several impor-
tant decisions have been made under the combined inﬂu-
ence of EASL and patients’ groups at the European
level; last, but not least, liver diseases have now more
weight in the research funding calls of the Commission’s
7th Framework Programme. These eﬀorts must now be
sustained and extended.
The extension and growing complexity of EASL
activities made professionalization of EASL administra-
tion and everyday handling an absolute and urgent
need. In this respect, the opening, in January 2009, of
the EASL Oﬃce in Geneva, is the most important step
forward of our association since its creation. The EASL
Oﬃce will provide the Association with the operational
capacity to function with dedicated, faithful, indepen-
dent personnel. The administrative, ﬁnancial, politicaland operational tasks of EASL will be handled by four
full-time professionals, while two additional EASL oﬃ-
cers will run the central oﬃce of the Journal of Hepatol-
ogy that will become operational with the next
international editorial team. This new structure has
already profoundly transformed the management of
the Association, which now reaches the level of organi-
zation of the most successful international scientiﬁc
societies.
Taking into account EASL growth and extended mis-
sions, the EASL Governing Board has been working,
with the EASL staﬀ and branding professionals, to give
EASL a new uniﬁed brand identity. The starting point
for this branding process has been the creation and
design of a new EASL logo, which will be phased in over
the next weeks to months through our diﬀerent publica-
tions, meetings, our website and other communication
tools. This was the last, important symbolic change of
a long list.
2. EASL’s challenges
EASL’s current relative wealth is the result of the
growing interest over the past few years of the pharma-
ceutical industry in viral and tumoral liver diseases in a
relatively liberal environment regarding both scientiﬁc
society funding and sponsored meeting attendance.
Worrisome signals recently came from North America
indicating that this situation might not last for ever.
The diﬃcult economic times, ongoing and expected
pharmaceutical company mergers, as well as foreseeable
changes in the European regulatory environment make
the current EASL economic model unviable on the
mid to long term. The establishment of a strong and eﬃ-
cient fundraising policy, independent of direct sponsor-
ship by the pharmaceutical industry, is the principal
challenge our association will have to face in the coming
years. The new EASL leadership and the EASL Oﬃce
are strongly committed to this vital task.
Despite being an association of individuals, EASL
will have to face crucial national and international chal-
lenges. Internally, the inﬂuence, representation, and par-
ticipation of individual EASL members from the smaller
west European nations and, most importantly, from east
European nations will have to substantially increase. A
better gender balance is also needed. Externally, the
reinforcement of the links with AASLD is an absolute
priority. Continental scientiﬁc societies represent the
only credible academic counter-power against govern-
ment and private sector interests. The goal of Clinical
Practice Guidelines written together by both societies
is achievable. Speaking with one voice to international
stakeholders and policy makers, controlling the ﬂow of
scientiﬁc information and being able to generate
independent international clinical trials addressing sci-
entiﬁc and clinical practice issues is possible. In this
1070 J.-M. Pawlotsky / Journal of Hepatology 50 (2009) 1067–1070respect, the creation of Clinical Research Networks or
Consortia and the establishment of strong transatlantic
relationships is a credible and useful approach. The
recent creation of an EASL-Chronic Liver Failure
(EASL-CLIF) Consortium, tightly connected with a
similar network in North America, is a ﬁrst step in the
right direction. Reinforcement of our links with other
societies, such as ALEH and APASL, either bilateral
or within the Global Alliance, is also an important chal-
lenge if one thinks that the vast majority of liver patients
live in these areas, where the level of clinical hepatology
is high, the economy growing and bench research
booming.
The relationship between hepatology and gastroen-
terology has always been complex and emotive. The
question of making hepatology an independent ‘‘spe-
cialty” in Europe has been raised a number of times.
EASL’s position is that this issue can be addressed only
at a national level, should it be desirable. Years ago,
EASL joined a number of other, generally smaller, sci-
entiﬁc societies, in the United European Gastroenterol-
ogy Federation (UEGF), the role of which was to
organize the yearly United European Gastroenterology
Week (UEGW), a scientiﬁc and educational event in
which EASL was responsible for the liver programme.
Recent reorganizations and initiatives indicate that
UEGF may evolve to become the European Gastroen-
terology society. This is excellent news as such a society
is needed. Nevertheless, the move implies that EASL
will have to leave this organization and establish a
new, constructive relationship with it. There is room in
Europe for two independent scientiﬁc societies which
do not overlap in their objectives and collaborate to
organize events whereby each society is responsible for
its own programme. Our American colleagues have
shown us that this was possible. EASL is ready for these
changes.3. Farewell
I took up the position of EASL Scientiﬁc Secretary in
2005 without any particular joy or happiness. Reaching
this position had never been a dream or a career objec-
tive. It just happened, thanks to Jordi Bruix, and I was
aware of the enormous task and challenges ahead. I am
now leaving the position of EASL Secretary General
with pride, joy and no regrets. Leading EASL has been
an extraordinarily exciting experience, but EASL is not
everything, and other exciting experiences are ahead. I
am looking forward to these new challenges. I would
like to thank the Governing Board members I worked
with, many of whom became my friends. Some days
(and nights) will remain in our memories for ever. I
would like to thank Laetitia Bru, who helped me run
EASL for 4 years through calm and storms, for her
courage, involvement and tenacity: EASL owes her a
lot. I would like to thank Gre´goire Pavillon who
accepted the task of building the new EASL Oﬃce with
passion and enthusiasm. I would like to thank the edito-
rial team of the Journal of Hepatology for having made a
better and better journal and supported EASL’s growth
and changes. I would like to thank the EASL members
for their support and the participants in all our activities
who, day after day, build the success of EASL. I would
ﬁnally like to thank Daniel Dhumeaux, my mentor, all
my collaborators, and my family. Doing this job for
four years needed support from the ones who count.
Through the successes and failures, the good decisions
and mistakes, I have learnt, and for this, I would like
to thank you all.
Long life and good luck, EASL !
Paris, April 3, 2009
